Federal Register of Legislation - Australian Government

Primary content

PB 12 of 2019 Other as made
This instrument amends Schedule 1 of the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).
Administered by: Health
Registered 27 Feb 2019

PB 12 of 2019

 

National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2019 (No. 2)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated 26 February 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2019 (No. 2).

(2)          This Instrument may also be cited as PB 12 of 2019.

2          Commencement

This Instrument commences on 1 March 2019.

3          Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).

 


Schedule 1       Amendments

[1]        Schedule 1, after entry for Bicalutamide in the form Tablet 50 mg

insert:

Bictegravir with emtricitabine with tenofovir alafenamide

Tablet containing bictegravir 50 mg with emtricitabine 200 mg with tenofovir alafenamide 25 mg

20

60

5

 

[2]        Schedule 1, after entry for Insulin lispro in the form Injections (human analogue), cartridges, 100 units per mL, 3 mL, 5

insert:

Insulin lispro

Injections (human analogue), pre-filled pen, 200 units per mL, 3 mL, 5

20

5

1

 

[3]        Schedule 1, after entry for Ivabradine in the form Tablet 7.5 mg (as hydrochloride)

insert:

Ixekizumab

Injection 80 mg in 1 mL single dose pre-filled pen

20

2

2

 

[4]        Schedule 1, after entry for Risedronic acid and calcium in the form Pack containing 4 tablets risedronate sodium 35 mg and 24 tablets calcium 500 mg (as carbonate)

insert:

Rivaroxaban

Tablet 10 mg

20

30

5

 

[5]        Schedule 1, after entry for Varenicline in the form Tablet 1 mg (as tartrate)

insert:

Venetoclax

Tablet 100 mg

20

120

5